The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 16.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 16.
Number 5: Insurer Anthem has announced that it is parting ways with Express Scripts in order to found its own pharmacy benefit management company, IngenioRx.
Number 4: The Senate Health, Education, Labor and Pensions Committee heard testimony from pharmaceutical manufactures and the supply chain in a full committee hearing on Tuesday, facing pointed questions about drug rebates.
Number 3: Switching patients from originator biologics to biosimilars has been shown to have an association with the so-called “nocebo” effect, in which negative expectations lead to worse outcomes.
Number 2: Dr Angus Worthing, practicing rheumatologist and chair of the American College of Rheumatology's Government Affairs Committee, spoke to The Center for Biosimilars® about the need for Congress to adequately fund the FDA and to provide adequate budget for healthcare.
Number 1: Contributor Amanda Forys of Xcenda explains the challenges that lie ahead for the biosimilars market.
Finally, last week, our newsletter asked for your thoughts on whether transfers of drug patents to sovereign entities should be permitted under US law. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.